This article first appeared on GuruFocus .
-
Revenue:INR314 crore, a 2% decline QoQ.
-
Gross Margin:51%, with an absolute gross margin of INR160 crore, an 8% decline QoQ.
-
Operating Costs:Increased by INR9 crore QoQ, including a one-time upgradation cost of INR4 crore.
-
EBITDA:INR35 crore, reflecting a 39% degrowth QoQ.
-
Debt Reduction:Reduced by INR153 crore during H1 FY26, a 20% reduction in opening debt.
-
Regulated Market Sales:75% of overall sales.
-
Warning! GuruFocus has detected 5 Warning Signs with BOM:541540.
-
Is BOM:541540 fairly valued? Test your thesis with our free DCF calculator.
Release Date: November 05, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Solara Active Pharma Sciences Ltd ( BOM:541540 ) successfully cleared a US FDA audit at their Mangalore facility with only two minor procedural observations.
-
The company maintains a strong gross margin profile of 51%, despite short-term disruptions.
-
Solara Active Pharma Sciences Ltd ( BOM:541540 ) has reduced its debt by INR153 crore during H1 FY26, reflecting a 20% reduction in opening debt.
-
The company is focusing on sustainable, scalable, and reliable growth, with an emphasis on operational deliveries and business expansion.
-
Solara Active Pharma Sciences Ltd ( BOM:541540 ) has a strong presence in regulated markets, contributing 75% of overall sales.
Negative Points
-
The company's financial performance was impacted by an unscheduled operational shutdown at the Mangalore facility, leading to delayed deliveries and reduced volumes.
-
There was a marginal decline in revenue by 2% QoQ, with a significant impact on EBITDA, which saw a degrowth of close to 39% QoQ.
-
Operating costs increased by INR9 crore QoQ, driven by annual cost increases and one-time upgradation costs.
-
The company experienced a decline in gross margins due to a change in product mix and deferred delivery of higher-margin products.
-
Solara Active Pharma Sciences Ltd ( BOM:541540 ) faces liquidity challenges, with net current liabilities exceeding assets by over INR70 crore.
Q & A Highlights
Q: Could you explain the decline in gross margins and whether you expect to return to the guided range of 53% to 55%? Also, what is driving the increase in fixed costs? A: The gross margin decline, even after adjusting for deferred sales, is due to a change in product mix. We are confident of maintaining a healthy gross margin above 51%. The increase in fixed costs is driven by annual inflationary hikes and increased volumes, which have reduced the need for plant shutdowns. We expect costs to stabilize around INR117 crore to INR120 crore per quarter. - Sarat Kumar, CFO
Q: How long was the Mangalore facility shutdown, and what benefits did it bring? A: The shutdown lasted three to four weeks in August. It was part of a major upgradation exercise for our aging Mangalore facility, costing around INR4 crore to INR5 crore. This upgrade was followed by a successful US FDA audit with only two minor observations. - Sandeep Rao, CEO
Q: Why was preventive maintenance not planned to avoid a Q2 hit, and was any portion of the INR40 million shutdown cost capital in nature? A: The shutdown was initially planned for one week, but additional areas required attention, extending it to three to four weeks. External climatic challenges also contributed. The INR40 million cost was entirely operational, with capital upgrades accounted separately. - Sarat Kumar, CFO
Q: What is the outlook for reaching historical peak revenue levels, and do you have any guidance for this financial year? A: While reaching INR450 crore in quarterly revenue is an aspirational target, our focus is on EBITDA levels. We aim for a 10% sales increase and 15% to 20% EBITDA growth, sticking to our Q1 outlook. - Sandeep Rao, CEO
Q: How many DMF filings do you have, and what are your plans for launching new products? A: We have around 90 to 95 DMF filings in the US, with 35 to 40 active products. We are developing new products, but it will take two to three years to bring them to market due to regulatory processes. - Sandeep Rao, CEO
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
